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Abstract
The phosphodiesterases (PDEs) are a superfamily of enzymes that regulate spatio-temporal 
signaling by the intracellular second messengers cAMP and cGMP. PDE2A is expressed at high 
levels in the mammalian brain. To advance our understanding of the role of this enzyme in 
regulation of neuronal signaling, we here describe the distribution of PDE2A in the rat brain. 
PDE2A mRNA was prominently expressed in glutamatergic pyramidal cells in cortex, and in 
pyramidal and dentate granule cells in the hippocampus. Protein concentrated in the axons and 
nerve terminals of these neurons; staining was markedly weaker in the cell bodies and proximal 
dendrites. In addition, in both hippocampus and cortex, small populations of non-pyramidal cells, 
presumed to be interneurons, were strongly immunoreactive. PDE2A mRNA was expressed in 
medium spiny neurons in neostriatum. Little immunoreactivity was observed in cell bodies, 
whereas dense immunoreactivity was found in the axon tracts of these neurons and their terminal 
regions in globus pallidus and substantia nigra pars reticulata. Immunostaining was dense in the 
medial habenula, but weak in other diencephalic regions. In midbrain and hindbrain, 
immunostaining was restricted to discrete regions of the neuropil or clusters of cell bodies. These 
results suggest that PDE2A may modulate cortical, hippocampal and striatal networks at several 
levels. Preferential distribution of PDE2A into axons and terminals of the principal neurons 
suggests roles in regulation of axonal excitability or transmitter release. The enzyme is also in 
© 2012 IBRO. Published by Elsevier Ltd. All rights reserved.
*Corresponding author. Address: Mnemosyne Pharmaceuticals Inc., One Davol Square, Suite 200, Providence, RI 02903, USA. Tel: 
+1-860-572-1343; fax: +1-401-831-0022.
†Present address: Critical Path Institute, 1730 East River Road, Tucson, AZ 85718-5893, USA.
‡Present address: University of South Carolina School of Medicine, Department of Pharmacology, Physiology & Neuroscience, VA 
Building 1, Third Floor, Columbia, SC 29208, USA.
§Present address: Selventa, One Alewife Center, Cambridge, MA 02140, USA.
HHS Public Access
Author manuscript
Neuroscience. Author manuscript; available in PMC 2015 April 26.
Published in final edited form as:













forebrain interneurons, and in mid- and hindbrain neurons that may modulate forebrain networks 
and circuits.
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Introduction
The cyclic nucleotides cAMP and cGMP are ubiquitous intracellular second messengers that 
regulate a remarkable diversity of biological processes. Utilization of only two molecules for 
diverse functions is dependent upon the ability to maintain the spatial and temporal 
specificity of these signals. Key to this specificity is the phosphodiesterase (PDE) 
superfamily of enzymes, which hydrolyze cAMP and cGMP to terminate their action (Conti 
and Beavo, 2007; Omori and Kotera, 2007). Eleven families of mammalian PDEs are 
encoded by 21 genes that, through alternative RNA splicing, give rise to well over 60 
isoforms that differ in substrate specificity and allosteric regulation. Each PDE gene has a 
unique expression pattern at the tissue and cellular level (Bingham et al., 2006). 
Furthermore, the subcellular distribution of isoforms is restricted and may be subject to local 
regulation, as has been shown for PDE4 (Lynch et al., 2006). Thus, the precise localization 
of specific PDEs may be crucial for control of cyclic nucleotide signaling. PDE families in 
the brain exhibit distinct but overlapping regional and circuit distributions (Menniti et al., 
2006; Lakics et al., 2010; Kelly, 2012); the distribution of specific isoforms can provide 
important clues regarding their roles in brain function. The goal of the present study was to 
identify the cellular and subcellular distribution of PDE2A, an isoform notable for its 
exceptionally high expression in the brain.
PDE2A is a dual substrate enzyme, capable of degrading both cGMP and cAMP 
(Sonnenburg et al., 1991; Rosman et al., 1997). The enzymatic activity of PDE2A may be 
regulated allosterically by cGMP binding to an N-terminal GAF (cGMP-specific and -
stimulated PDEs, Anabaena adenylyl cyclases, and Escherichia coli FhlA) domain to 
increase hydrolytic activity (Stroop and Beavo, 1991; Juilfs et al., 1999). This provides a 
potential mechanism by which PDE2A may exert regulatory feedback inhibition of cGMP 
signaling, as well as cross-talk regulatory inhibition of cAMP signaling by cGMP 
(MacFarland et al., 1991; Stroop and Beavo, 1991). In a survey of the expression pattern of 
PDE2A protein in multiple mammalian species (Stephenson et al., 2009), we found that by 
far the highest levels of protein were in the brain, as suggested by previous data on mRNA 
expression (Sonnenburg et al., 1991; Rosman et al., 1997; Van Staveren et al., 2003). In our 
2009 study, we reported that the expression pattern of PDE2A in the brain is generally 
consistent across species from rodent to primate. We here present a more detailed analysis of 
the distribution of this enzyme in the brain, using rat as a representative species.
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Crl:CD(SD)IGS BR rats (strain code 001) were obtained from Charles River Laboratories 
(Kingston, NY, USA). All rats used in this study were housed in a facility accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care International, and 
were used in accordance with an approved animal care and use protocol, the Institute for 
Laboratory Animal Research Guide for the Care and Use of Laboratory Animals (National 
Research Council, 1996), and all applicable regulations.
In situ hybridization
Autoradiographic in situ hybridization with 35S-labeled oligonucleotide antisense probes 
was conducted as previously described (Kelly and Deadwyler, 2002; Kelly et al., 2010). 
Three distinct probes specific to unique sequences in PDE2A were analyzed; all showed 
overlapping patterns of mRNA expression. For the data presented here, the oligonucleotide 
probe corresponding to base pairs 1612–1573 of PDE2A was chosen for a detailed analysis 
(NM_001143847.1; Antisense: 5-
GGGATGTTCAGGATCTGGCCCGTGGTCGCCACGTGGCC CG-3′). Rats were 
euthanized with carbon dioxide gas, and exsanguinated; their brains were rapidly frozen. 
Sections of 20 lm were cut, post-fixed, defatted, and dehydrated, followed by incubation 
with the 35S-labeled oligonucleotide probe. Slides were apposed to film for 7 days, and 
images acquired on a high-resolution digital scanner. Similar patterns of hybridization were 
observed in mouse tissue with an additional antisense/sense probe pair corresponding to 
nucleotides 1820–1781 of NM_001143848 (M. P. Kelly, unpublished observation). Sense 
probes used in a similar manner yielded no specific hybridization signal.
Immunohistochemistry
The procedures were as described previously (Stephenson et al., 2009). Rats were 
euthanized with a lethal dose of sodium pentobarbital and perfused transcardially with 
phosphate buffer followed by 4% buffered depolymerized paraformaldehyde. Brains were 
post-fixed by immersion in the same fixative, processed according to established protocols, 
and embedded in paraffin; 5-lm sections were cut and deposited onto charged glass slides. 
Two rats were used for the immunohistochemical mapping study. An additional six rats 
were used to assess PDE2A immunoreactivity in specific regions of interest, and to evaluate 
the expression of PDE2A relative to that for microtubule-associated protein 2 (MAP2). All 
immunohistochemical procedures were performed on an autostainer (Dako North America, 
Inc., Carpinteria, CA, USA) to ensure consistency across slides. One series of slides from 
the immunohistochemical mapping study was stained with Cresyl Violet to assess 
cytoarchitecture.
Antibodies—The PDE2A antibody used was PD2A-101AP obtained from FabGennix Inc. 
(Frisco, TX, USA). This rabbit polyclonal is directed against an 18 amino acid sequence 
from the C terminal of PDE2A (aa909-926, Ensemble peptide ID ENSP00000334910) that 
is conserved across species and is not present in other PDE family members. This antibody 
was characterized extensively in our previous study (Stephenson et al., 2009), which 
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reported that: (1) PD2A-101AP recognized a single band of the appropriate molecular 
weight of ∼100 kDa in brain extracts in Western blot analyses, (2) anti-PDE2A staining of 
rodent brain tissue was absent following pre-adsorption with PDE2A antigenic blocking 
peptide (P-PD2A100, FabGennix), (3) no staining was observed in fetal brain tissue from 
PDE2A-specific knockout mice, and (4) identical staining patterns were observed with a 
monoclonal antibody made against a different portion of the PDE2A protein (Stephenson et 
al., 2007).
A mouse monoclonal antibody specific for MAP2 was used to study co-localization with 
PDE2A by dual fluorescence immunohistochemistry. HM-2 (Sigma Aldrich, St. Louis, MO, 
USA) was raised against rat MAP2; it is reported to recognize all isoforms of this protein 
(manufacturer's information).
Immunoperoxidase staining—To expose antigenic sites, tissue sections were heated in 
a Biocare Decloaking Chamber (Biocare Medical, Concord, CA, USA) to 120°C at 12-15 
psi for 30 s followed by a gradual cool down to 85 °C in Citra Antigen Retrieval pH 6 
(Biogenex, San Ramon, CA, USA). Immunostaining was performed by incubating tissues 
with anti-PDE2A at a dilution of 1:100 for 60 min at room temperature. Rabbit IgG (Vector 
Laboratories, Burlingame, CA, USA) was used as negative control, at the same 
concentration as anti-PDE2A. Antibody binding sites were detected by incubating tissues 
with a biotinylated secondary goat anti-rabbit antibody (Vector Laboratories) at a 
concentration of 1:150 for 45 min followed by 30-min incubation with Elite® ABC (Vector 
Laboratories). Dako Liquid DAB+ (Vector Laboratories) was used to visualize PDE2A 
immunoreactivity. Mayer's hematoxylin (Dako) was used as a counterstain.
Double-label immunofluorescence—The comparative distribution of PDE2A and 
MAP2 was analyzed by confocal fluorescence microscopy. To expose antigenic sites, tissue 
sections were heated as above in Citra Antigen Retrieval pH 6. PDE2A antibody (1:100) 
was co-incubated with anti-MAP2 (1:20,000) antibody for 60 min. To detect PDE2A, a 
biotinylated goat anti-rabbit secondary antibody was applied at 1:150 for 45 min followed 
by incubation with streptavidin Alexa 488 (Invitrogen, Carlsbad, CA, USA) at 1:400 for 30 
min. MAP2 antibody was detected by incubating with a goat anti-mouse Alexa 568 
(Invitrogen) secondary antibody at 1:400 for 30 min. All sections were mounted with 
Vectashield (Vector Laboratories) to delay fading, and DAPI was present as a counterstain 
to identify cell nuclei (not shown).
Microscopy—All stained slides were examined qualitatively using standard microscopy. 
Images of immunoperoxidase-stained sections were acquired using an Aperio Scanscope XT 
system (Aperio Technologies, Vista, CA, USA). Digital images were captured via a 1D 
CCD line scan under constant exposure and light settings. For each marker, the area of 
interest was specified and autofocus points were manually indicated on each slide. All slides 
were then scanned in the automated one-touch mode. Digital images were stored in the svs 
format (compression quality = 70) and managed in the Spectrum database. High 
magnification photomicrographs were captured with a Nikon E-100 (Nikon Instruments, 
Inc., Melville, NY, USA) using a SPOT RT camera. Fluorescently stained sections were 
analyzed by confocal microscopy on a Leica TCS-SP laser scanning confocal microscope 
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(Leica Microsystems Inc., Exton, PA, USA) equipped with argon, krypton, and UV lasers, 
which allowed excitation at 488, 568, and 358 nm wavelengths for the detection of Alexa 
488, Alexa 568, and DAPI, respectively.
Results
PDE2A mRNA
In situ hybridization demonstrated that message for PDE2A was present at high levels in 
gray matter throughout the forebrain (Fig. 1; sense control (not shown) revealed no 
significant signal). PDE2A mRNA was highly expressed in the internal granule layer of the 
olfactory bulb, and in the anterior olfactory nucleus (Fig. 1A, B). In neocortex, signal was 
stronger in superficial than deep layers, and was especially intense over the tightly packed 
layer of neurons in piriform cortex and the pyramidal cell layer of the hippocampus (Fig. 
1C–G). Signal was less intense over the granule cells of the dentate gyrus (Fig. 1F, G). 
Message was intense and diffusely distributed throughout the amygdala and neostriatum, but 
very weak or absent in globus pallidus (Fig. 1E) and substantia nigra (Fig. 1G). PDE2A 
mRNA was expressed at very high levels in the medial habenula (Fig. 1F), but at low levels 
throughout the rest of the diencephalon and mesencephalon (Fig. 1E–G).
PDE2A immunostaining in forebrain
Immunoperoxidase reaction product was heterogeneously distributed in the rat forebrain, as 
illustrated in coronal sections at low magnification (Fig. 2). PDE2A was found in the 
plexiform, granule cell and ependymal layers of the olfactory bulb (Fig. 2A). 
Immunostaining was especially strong in supragranular layers of neocortex, olfactory 
tubercle (Fig. 2C), globus pallidus (Fig. 2D), habenula (Fig. 2G), subiculum, and substantia 
nigra (Fig. 2H). Intense staining in the pallidum and substantia nigra was noteworthy, since 
very little PDE2A message was detected in these regions (Fig. 1E, G). DAB product was 
essentially absent from a coronal slice exposed to a rabbit IgG control antibody processed in 
parallel (Fig. 2F).
Neocortex
Immunostaining in neocortex was conspicuously laminar, as illustrated for somatosensory 
cortex in Fig. 3A. PDE2A was at highest density in layer I, extending through the neuropil 
of layers II–III. Weaker staining was seen in the neuropil of layer V, and low levels of 
diffuse immunoreactivity were present in layer IV and the innermost cortical region. At 
higher magnification (Fig. 3B), the neuropil staining appeared granular, suggesting 
localization to synaptic puncta. Immunostaining was distinctly weaker in the cell bodies and 
primary dendrites of the large majority of cells relative to the neuropil. From their 
morphology, these weakly stained cells are likely glutamatergic pyramidal neurons. In 
favorable cases, the cell body and proximal apical dendrite of pyramidal neurons appeared 
coated with immunopositive puncta (Fig. 3B, white arrow). Strongly immunopositive cell 
bodies scattered amongst the numerous weakly stained neurons (Fig. 3C, black arrow) were 
not of pyramidal morphology and were likely local circuit neurons.
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PDE2A immunoreactivity was strong in stratum oriens of CA1, stratum lucidum of CA3 
(the region of mossy fiber terminals), and the hilar region of the dentate gyrus (Fig. 4A). 
Staining in the molecular layer of the dentate gyrus was organized into three sharply defined 
zones, including a weakly stained inner, moderately stained middle, and strongly stained 
outer layer (Fig. 4A, C). Immunoreaction was largely excluded from the densely packed 
cells of the pyramidal cell layer in Ammon's horn and the granule cell layer of dentate gyrus 
(Fig. 4A–C). Similarly, immunoreaction was weak or undetectable in the proximal dendrites 
of the pyramidal cells (Fig. 4B). However, scattered densely stained somata were seen in the 
pyramidal cell layer, particularly in CA3 (Fig. 4A).
The anatomy of the mossy fiber termination in CA3 afforded an opportunity to investigate 
the subcellular distribution of PDE2A. We used dual-label immunofluorescence confocal 
microscopy to compare the distribution of PDE2A to that of the dendritic marker MAP2 
(Fig. 5). Puncta immunopositive for PDE2A (green channel in Fig. 5A, C) were diffusely 
distributed throughout most of this region, with discrete areas that contained little or no 
immunoreactivity. There was virtually no overlap between PDE2A and MAP2 
immunoreactivity; in fact, many of the large dendritic shafts defined by MAP2 
immunoreactivity corresponded to areas that were devoid of PDE2A (Fig. 5A–C).
Piriform cortex and amygdala
PDE2A immunostaining was diffusely distributed throughout the neuropil in the piriform 
cortex (Fig. 6). Diffuse staining was also observed throughout the amygdaloid complex, 
which merged without obvious border into the caudate nucleus. The exception was the 
sharply delineated anterior cortical amygdaloid nucleus (ACo), which exhibited stronger 
immunostaining than the surrounding tissue. Cell bodies throughout the region of the 
piriform cortex and amygdala exhibited markedly weaker immunoreactivity than the 
neuropil, as particularly obvious in layer II of piriform cortex. The exception was a band of 
scattered immunopositive cell bodies running mediolaterally through the amygdaloid 
complex and then dorsally along its lateral border (arrows, Fig. 6).
Striatum and striatal projections
PDE2A immunostaining was distributed throughout the neuropil of the neostriatum (Fig. 
7A). There was no obvious regional variation in density in either the dorsal/ventral or 
medial/lateral axis, nor was there evidence of differential density that might suggest 
preferential localization in a striatal subcompartment. Staining was excluded from the 
bundles of myelinated fibers that run through the striatum. Immunostaining was markedly 
stronger in the striatal projection regions of the globus pallidus and substantia nigra pars 
reticulata than in the neostriatum (Fig. 7). Within substantia nigra, immunostaining was 
markedly higher in reticulata than in pars compacta (Fig. 7B), and was very weak in the 
ventral tegmental area. In contrast to the neuropil, somata in neostriatum, globus pallidus 
and substantia nigra generally showed little or no immunostaining. The interpeduncular 
nucleus (which receives a projection from the medial habenula) was very densely stained 
(Fig. 7B).
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PDE2A immunoreactivity was heterogeneously distributed throughout the midbrain (Fig. 8). 
Diffuse immunostaining of the neuropil was observed in the external cortex of the inferior 
colliculus, central gray region, and in the region ventrolateral to the central gray (Fig 8A), 
and on the ventromedial edge of the section, associated with the pyramidal tract. 
Immunoreactivity was observed in cell bodies and neuropil in the dorsal raphe nucleus, as 
well as dense filamentous staining in the midline just ventral to the stained raphe somata 
(Fig. 8B). Somatic staining on a background of weakly stained neuropil was seen in the 
region of the lateral dorsal tegmentum (Fig. 8C, D). Only light staining was seen in the 
neuropil of the locus coeruleus, and cell bodies in this region were unstained. More caudally, 
the neuropil associated with the lateral and superior vestibular nuclei was stained, as were 
the fibers of the pyramidal tract (Fig. 9A).
Cerebellum
Uniform light staining was observed in the molecular layer of cerebellar cortex (Fig. 9A). At 
higher magnification, this staining resolved into scattered puncta and thin fibers running 
perpendicular to the axis of the Purkinje cell layer (Fig. 9B). Purkinje cells stained very 
lightly (Fig. 9B, arrowhead), whereas a restricted subset of strongly immunopositive smaller 
interneurons was scattered throughout the molecular and granule cell layers.
Spinal cord
PDE2A immunoreactivity was mainly confined to gray matter, though staining was also 
present in the dorsal corticospinal tract (Fig. 10). The highest density of immunostaining 
was seen in the neuropil of the dorsal horn, especially in laminae I–II. Scattered strongly 
immunopositive somata were visible throughout the spinal gray.
Vascular staining
The expression of PDE2A protein associated with blood vessels supplying the brain has 
been reported previously (Stephenson et al., 2009). We confirmed this observation in the 
present study; a particularly clear example is visible in Fig. 8D, where arrows point to 
several strongly immunopositive endothelial cells lining a small arteriole.
Discussion
The dual substrate phosphodiesterase PDE2A is highly expressed in the brain (Repaske et 
al., 1993; Yang et al., 1994; van Staveren et al., 2003; Stephenson et al., 2009; Lakics et al., 
2010; Kelly, 2012), suggesting a significant role for the enzyme in regulating neuronal 
signaling, and fostering interest in developing selective pharmacological inhibitors as 
potential neurotherapeutics (Menniti et al., 2006; Conti and Beavo, 2007; Omori and Kotera, 
2007; Schmidt, 2010). Unique insights into this physiology and pharmacology may be 
gained through detailed mapping of the distribution of PDE2A in the brain. The present 
study revealed a remarkably complex distribution of PDE2A, which was found to be 
expressed at varying intensity levels in different neuronal types and circuits throughout the 
neuraxis. Furthermore, the enzyme was found to be differentially distributed into neuronal 
subcellular compartments in a cell type-specific manner. These results provide an important 
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guide for ongoing investigations into the functions of PDE2A in the brain and in interpreting 
the effects of pharmacological inhibition of the enzyme on behavior, as discussed below.
PDE2A is most broadly expressed in subsets of glutamatergic principal neurons in the 
forebrain, as indicated by the distribution of mRNA (van Staveren et al., 2003 and present 
study). PDE2A mRNA is present in a high percentage of cells throughout neocortex, 
consistent with expression in the pyramidal neurons that comprise the major neuronal 
populations in this structure. PDE2A mRNA is also expressed at notably high levels in the 
majority of principal neurons of allocortex, both in piriform cortex and in the pyramidal cell 
layer of the hippocampus. PDE2A mRNA is present in the dentate granule cells, but at lower 
levels than in the hippocampal pyramidal neurons. On the other hand, PDE2A is only 
weakly expressed or absent in other classes of forebrain glutamatergic neurons. For 
examples, little or no expression of PDE2A mRNA was observed in thalamus, which 
contains populations of glutamatergic neurons that project to cortex and striatum, and in the 
hilus of the hippocampus, which contains the glutamatergic mossy cells (Buckmaster et al., 
1996).
The distribution of PDE2A protein in the cortex and hippocampus is consistent with 
expression by the different classes of glutamatergic neurons that express PDE2A mRNA, if 
attention is focused on major projections from these neurons. This is especially clear for the 
hippocampus, where variations in the density of PDE2A immunoreactivity corresponded to 
distinct axonal tracts. The highest density was found in the subiculum, hilus, and the region 
of the mossy fiber terminals in CA3, the major projection target of dentate granule cells. In 
the stratum moleculare of the dentate gyrus, PDE2A was higher in the outer two thirds, 
corresponding to the terminal zone of perirhinal cortical neurons of the perforant path. In the 
hippocampus proper, PDE2A staining was notable in the fibers of the alveus, which collects 
the axons of pyramidal neurons projecting out of the hippocampus via the fimbria/fornix and 
the axons of CA1 pyramidal neurons projecting to the subiculum. In contrast, PDE2A 
staining was weak in the majority of cell bodies and proximal dendrites in the hippocampus 
and dentate gyrus, despite the strong expression of PDE2A mRNA in these neurons.
Taken together, the immunohistochemical analysis of the hippocampus suggests that 
PDE2A is preferentially distributed to axons and terminals of the glutamatergic projection 
neurons that express the protein. To further interrogate this hypothesis, we took advantage of 
the unique anatomy of the dentate granule cell projection giving rise to the mossy fiber 
terminals that synapse onto dendrites of CA3 pyramidal neurons. In double label 
immunofluorescence experiments, we found that the dense zones of PDE2A 
immunoreactivity in this region did not overlap with the dendritic marker, MAP2, indicating 
that PDE2A is localized selectively to the presynaptic mossy fiber terminals. Other lines of 
evidence also suggest that PDE2A is predominantly localized to presynaptic terminals in the 
hippocampus. Using differential centrifugation, Xie et al. (2006) found PDE2A associated 
with synaptosomes derived from the rat brain. More recently, Russwurm et al. (2009) 
confirmed an association of PDE2A with synaptosomal membranes from the rat brain, and 
demonstrated overlap of PDE2A immunoreactivity with the presynaptic protein 
synaptophysin in primary cultures of rat hippocampal neurons.
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The distribution of PDE2A in neocortex is consistent with localization predominantly in 
axons and terminals of the principal neurons. PDE2A immunoreactivity was found at 
highest levels in outer cortical layers, as well as in a band through upper layer V. Lower 
levels of expression were observed in layer IV and in deep layers V and VI. As in the 
hippocampus, PDE2A was present at notably lower levels in pyramidal cell bodies and 
proximal dendrites than in the surrounding neuropil. This pattern suggests that the laminar 
neuropil staining resides within intracortical axons and terminals emanating from principal 
neurons in these regions. However, this hypothesis bears further investigation using 
techniques suited to resolving the location of immunoreactivity at individual synapses. 
PDE2A immunoreactivity was largely absent from white matter tracts through basal ganglia, 
and was present at rather low levels in the pyramidal tract in the brainstem and spinal cord, 
suggesting that PDE2A may be expressed at lower levels in layer V pyramidal neurons that 
project out of neocortex.
Localization of PDE2A to an axonal/presynaptic compartment in glutamatergic pyramidal 
neurons positions the enzyme to regulate presynaptic forms of plasticity. In the mossy fiber 
terminals of CA3, cAMP modifies vesicle release probability during induction of long term 
potentiation (LTP) (Nicoll and Schmitz, 2005). This form of presynaptic plasticity is also 
observed at corticostriatal synapses (Nicoll and Schmitz, 2005). cGMP signaling is also 
implicated in the regulation of presynaptic plasticity (Feil and Kleppisch, 2008). Indeed, 
PDE2A inhibition is reported to potentiate the induction of LTP at the Schaeffer 
collateral/CA1 synapse in slices of the rat hippocampus (Boess et al., 2004). It will be of 
interest to further investigate PDE2A localization to presynaptic glutamatergic terminals 
throughout the cortex and hippocampus, the mechanisms that underlie such localization 
(Russwurm et al., 2009), and to define the role through which the enzyme may regulate 
synaptic plasticity.
In contrast to the observation that the majority of neuronal cell bodies in the forebrain had 
low levels of PDE2A staining relative to the neuropil, several distinct populations of cells 
were observed with strong somatic immunostaining. These cells were particularly prevalent 
in the CA3 region of the hippocampus and in a band scattered along the ventral border of the 
lateral and central amygdaloid nucleus. Such cells were also scattered throughout the 
neocortex. From their non-pyramidal shape, we speculate that these are local circuit neurons. 
Consistent with this hypothesis, we noted PDE2A-containing puncta lining cell bodies and 
proximal dendrites of pyramidal neurons in neocortex. The large majority of synaptic 
contacts on cortical pyramidal neuron cell bodies are GABAergic (Jones and Hendry, 1984; 
Markram et al., 2004), suggesting the presence of PDE2A in such GABAergic terminals.
The other major cell type expressing PDE2A in the forebrain was found to be the striatal 
medium spiny neurons (MSNs). PDE2A mRNA was detected in most cells throughout the 
striatal complex, in agreement with previous studies (van Staveren et al., 2003). This mRNA 
distribution can be accounted for by expression in GABAergic MSNs, which comprise over 
90% of striatal neurons (Albin et al., 1989; Wilson, 2004). Moderate levels of PDE2A 
immunoreactivity were distributed throughout the neuropil of the neostriatum, whereas 
somata showed little evidence of immunostaining. In contrast, especially strong 
immunostaining was observed in the globus pallidus and substantia nigra, pars reticulata 
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(SNr). This is likely to arise from the MSN axons that terminate in these regions, since 
neither globus pallidus nor substantia nigra contained substantial levels of PDE2A mRNA. 
These findings suggest that PDE2A is also preferentially distributed to axons and terminals 
of striatal projection neurons.
Two subtypes of MSNs, comprising the direct and indirect output pathways of the striatum, 
terminate in the substantia nigra or globus pallidus, respectively (Albin et al., 1989; Reiner 
et al., 2010). The fact that PDE2A is present at equivalent levels in both of these projection 
regions indicates that the enzyme is expressed by both MSN subtypes, suggesting that 
PDE2A may regulate similar signaling cascades among all MSN subtypes. However, it has 
recently been reported that PDE2A mediates cross-talk between cAMP and cGMP signaling 
in response to dopamine D1 receptor activation (Lin et al., 2010), whereas PDE10A, another 
dual substrate PDE highly expressed by all MSNs (Seeger et al., 2003), preferentially 
regulates excitability in dopamine D2 receptor-expressing MSNs (Threlfell et al., 2009). 
Apparently, there must be mechanisms to segregate signaling by these PDEs in the two 
MSN subpopulations, despite uniform expression. The mechanisms that underlie this 
differential regulation are clearly of interest and bear further study.
In contrast to its strong expression in the forebrain, PDE2A is expressed at generally lower 
levels in midbrain, hindbrain, cerebellum, and spinal cord. A notable exception is the medial 
habenula. This discrete group of neurons contains high levels of PDE2A mRNA, and 
extremely dense PDE2A staining in the somata, axons within the fasiculus retroflexus, and 
terminals in the interpeduncular nucleus (Herkenham and Nauta, 1979). The substantial 
PDE2A immunoreactivity in raphe nuclei, but not locus coeruleus, suggests that the enzyme 
may play a role in serotonergic, but not noradrenergic, regulation. The distribution of 
PDE2A in the spinal cord is consistent with a role in pain modulation.
The high level of PDE2A expression in the brain has led to interest in selective inhibitors as 
potential therapeutic agents for CNS disorders (Menniti et al., 2006; Schmidt, 2010). 
PDE2A inhibition has been found to affect performance on cognitive behavioral tasks in 
rodents (Boess et al., 2004; Rutten et al., 2007; Domeklopacinska and Strosznajder, 2008; 
Rodefer et al., 2011) and in tasks that measure behaviors related to anxiety and depression 
(Masood et al., 2008, 2009). We speculate that the cognitive effects may reflect a role of the 
enzyme in the regulation of cortical and hippocampal glutamatergic transmission and 
plasticity. The PDE2A expression in putative GABAergic interneurons suggests that 
inhibitors may also impact network regulation. The expression of PDE2A in amygdala and 
putative serotonergic raphe neurons is noteworthy given the effects of PDE2A inhibition in 
animal models of depression and anxiety. The high expression of PDE2A in striatum 
suggests that it will be of interest to examine the behavioral effects of PDE2A inhibition in 
animal models sensitive to perturbation of striatal function, such as locomotor activity and 
addiction models; likewise, the very high levels of PDE2A in the habenulo-interpeduncular 
pathway may be relevant for response to aversive stimuli and nicotine dependence (Fowler 
and Kenny, 2012).
In summary, the present study provides a detailed map of PDE2A expression throughout the 
neuroaxis. This information provides an anatomical base for future studies of the signaling 
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cascades regulated by PDE2A at the cellular levels, and how such regulation is integrated 
over complex circuits. Neuroanatomical questions that remain include further investigation 
of the extent to which the enzyme is preferentially distributed into axons and terminals in 
pyramidal neurons and MSNs, the phenotype(s) of the putative GABAergic interneurons 
expressing the enzyme, and the identity of PDE2A-positive cell bodies and terminals outside 
of the forebrain. An important challenge will be to determine how the behavioral effects of 
systemically administered PDE2A inhibitors reflect effects summed over the complex 
distribution of the enzyme throughout the CNS. Harnessing this information may identify 
novel therapeutic uses for compounds that modulate PDE2A activity.
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DAPI 4′,6-diamidino-2-phenylindole
MAP2 microtubule-associated protein 2
MSNs striatal medium spiny neurons
PDE phosphodiesterase
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Distribution of PDE2A mRNA in coronal sections of rat brain, determined by in situ 
hybridization. Hybridization signal is black. Numbers at bottom of panels are distance from 
bregma, according to the atlas of Paxinos and Watson (1997). Message is high in cortical 
regions, striatum, and the habenula. Abbreviations used in the figures: A, cerebral aqueduct; 
ac, anterior commissure; Acb, n. accumbens; ACo, anterior cortical amygdaloid n; Amg, 
amygdaloid complex; AOn, anterior olfactory n.; BLA, basolateral amygdaloid n; CB, 
cerebellum; CC, central canal; cc, corpus callosum; Cg, cingulate cortex; Ce, central 
amygdaloid n; CP, caudate-putamen; CPu, caudate n. and putamen; dc, dorsal columns; dcs, 
dorsal corticospinal tract; DG, dentate gyrus; DR, dorsal raphe; FCx, frontal cortex; GC, 
granule cell layer; GP, globus pallidus; GPe; external part of globus pallidus; hb, habenula; 
Ht, hypothalamus; IC, inferior colliculus; IGr, internal granule cell layer of olfactory bulb; 
In, interpeduncular nucleus; LL, lateral lemniscus; LS, lateral septal n.; M, molecular layer; 
MR, median raphe; MVe, medial vestibular nucleus; OCx, occipital cortex; Opt, optic tract; 
PC, Purkinje cell layer; PCx, parietal cortex; Pir, piriform cortex; Pl, plexiform layer of 
olfactory bulb; Py, pyramidal cell layer; RF, rhinal fissure; SG, substantia gelatinosa; SL, 
stratum lucidum; SN, substantia nigra; SNc, substantia nigra, pars compacta; SNr, substantia 
nigra, pars reticulata; SO, stratum oriens; SR, stratum radiatum; Th, thalamus; 3v, 3rd 
ventricle; VH, ventral horn. Scale bar in G = 2.5 mm.
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Distribution of PDE2A immunoreactivity in coronal sections of rat brain, as determined by 
immunohistochemistry. Immunoreaction is brown; blue is counterstain. Numbers at bottom 
of panels are distance from bregma. Primary antibody was replaced by control IgG in F. 
Immunostaining is especially prominent in olfactory tubercule, globus pallidus, habenula, 
and substantia nigra (see text). Scale bar (panel H): 1 mm for panel A, 2 mm for all other 
panels. (For interpretation of the references to color in this figure legend, the reader is 
referred to the web version of this article.)
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Distribution of PDE2A immunostaining in somatosensory cortex (approximately 1 mm 
caudal to bregma). (A) Staining is strongest in superficial layers (cortical layers are denoted 
by Roman numerals). Black arrow points to a strongly stained non-pyramidal cell body in 
layer VI. (B) Higher magnification micrograph from II/III. Immunostaining is generally 
weaker in pyramidal cell bodies than in the surrounding neuropil. White arrow points to the 
pyramidal cell where granular staining appears to line cell body and the apical dendrite. (C) 
Black arrow points to a strongly immunopositive non-pyramidal cell located in upper layer 
IV of somatosensory cortex. Scale bars: Panel A = 500 μm; panel C (for B, C) = 10 μm.
Stephenson et al. Page 16














PDE2A immunoreactivity in hippocampus. (A) Low magnification view; staining is 
conspicuous in stratum oriens of CA1, the terminal field of mossy fibers in CA3, and the 
hilus of dentate gyrus. White and black arrows indicate the areas depicted in B and C (which 
were from different material). (B) Higher magnification view of CA1. Very weak staining in 
cell bodies and primary dendrites of hippocampal pyramidal neurons contrasts with stronger 
diffuse staining in the neuropil of stratum radiatum. (C) Detail from dentate gyrus. Note 
strong immunostaining in hilus, sublaminar pattern of staining in the molecular layer, and 
the low density of immunoreactivity in the cell bodies of granule cells. Scale bar in C = 500 
μm (for panel A); 250 μm (for B, C). Panel A is revised from a figure previously published 
(Stephenson et al., 2009), and is used with permission.
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Double immunofluorescent labeling for PDE2A (green) and MAP2 (red) in CA3 field of 
hippocampus (section is 3.5 mm caudal to bregma). (A) PDE2A channel; staining 
concentrates in stratum lucidum, likely associated with terminals of mossy fibers. (B) MAP2 
channel stains dendritic shafts. (C) Merged image; note minimal overlap between PDE2A 
and MAP2 fluorescence. Scale bar = 50 μm. (For interpretation of the references to color in 
this figure legend, the reader is referred to the web version of this article.)
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PDE2A immunoreactivity in the region of the amygdala (section is ∼2.5 mm caudal to 
bregma). A band of immunopositive neurons (indicated by arrows) runs between piriform 
cortex and amygdala, extending medially between anterior cortical and central/basolateral 
amygdaloid nuclei.
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PDE2A immunoreactivity in basal ganglia. (A) Staining in caudate-putamen is less dense 
than in globus pallidus (section 2 mm caudal to bregma). (B) Dense staining in substantia 
nigra (pars reticulata) contrasts with weak staining in substantia nigra pars compacta 
(section is 5.8 mm caudal to bregma). Very dense staining is also present in the 
interpeduncular nucleus. Scale bar = 1 mm.
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PDE2A immunoreactivity in midbrain. (A) Immunostaining is visible in superficial layers of 
inferior colliculus, the central gray, raphe nuclei, and pyramidal tract, though markedly 
weaker than in occipital cortex (visible at top); section is ∼8.5 mm caudal to bregma. (B) 
Higher magnification of boxed zone in A illustrates immunostaining in dorsal and median 
raphe. (C) A more caudal section (section ∼9.2 mm caudal to bregma); note labeling in the 
region of lateral dorsal tegmentum (black arrow). (D) Higher magnification of boxed zone in 
C shows immunopositive cell bodies. Black arrows point to immunostained endothelial cells 
lining an arteriole that runs through the section. Scale bar = 1 mm (A, C); 200 μm (B); 100 
μm (D).
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PDE2A immunoreactivity in hindbrain and cerebellum. (A) Low magnification view; 
staining is weak in cerebellar cortex, stronger in vestibular nuclei and pyramidal tract 
(section is 10.3 mm caudal to bregma). (B) Higher magnification view shows the molecular/
granule cell border of cerebellar cortex, illustrating weakly stained Purkinje cells (black 
arrows) and immunoreactive fibers and puncta in the molecular layer. Scattered strongly 
immunopositive neurons are visible in molecular and granule cell layers (readily identified 
by the densely packed blue cells). Scale bar = 1 mm (A); 100 μm (B). (For interpretation of 
the references to color in this figure legend, the reader is referred to the web version of this 
article.)
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PDE2A immunoreactivity in rostral spinal cord (section is from C2). Immunostaining is 
strongest in the neuropil of the superficial dorsal horn; some immunopositive neurons are 
scattered about the spinal gray, extending into ventral horn. Note light staining of fibers in 
corticospinal tract. Scale bar = 500 μm.
Stephenson et al. Page 23
Neuroscience. Author manuscript; available in PMC 2015 April 26.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
